“We have completed phase 1 of our trials. If P28 is found to be effective in phase 2 and 3 without showing any toxicity, the US Food and Drug Administration will give it market approval. This would take around five years, and the cost would come up to 100 million dollars,” he said. “Making peptide is expensive. Besides that, we also have to pay the cancer patients for letting us conduct the trials.”
Bacterially produced proteins or peptides such as P28 target only cancer cells, thereby showing very little toxicity but significant efficacy. This is the property that makes the bacterial protein drug unique, as compared to other drugs produced by the pharmaceutical industry.